Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

* Statistically significant reduction in sedation during the early post-operative period compared to morphine

* Statistically significant reduction in nausea in the female patient population compared to morphine

Cambridge, UK, 8th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company, announces additional data from post-hoc analysis of the recent Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. The Phase III data released on 20 February 2007 confirmed M6G's planned product profile and showed that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).

Sedation

Analysis of the sedation data from the M6G022 trial showed statistically significant reductions in sedation in the M6G group compared to morphine in the first four hours after surgery reaching a reduction of 15% at 4 hours (p=0.007). Discussions with clinicians support the view that this is a clinically important benefit. Opiates such as morphine are well known to induce sedation and respiratory depression. Excessive sedation in the early post-operative period is associated with depression of the respiratory system, which can, in some cases, be fatal.

Nausea in female patients

It is well established that female patients undergoing surgery have a higher risk of experiencing nausea and vomiting in the post-operative period. New data analysing the female patient group (approximately 70% of the patients in the M6G022 Phase III clinical trial) showed a statistically significant reduction in nausea in the period 6-24 hours after treatment (p=0.034). The overall incidence and severity of post-operative nausea in the M6G arm for both males and females was 27% less than that observed in the morphine arm but narrowly missed statistical significance, p=0.052 (versu
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine

Post Your Comments:
(Date:11/6/2009)...FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasd..., November 10, 2009 at 8:30 a.m. EST to discuss th...s outlook for the remainder of 2009. Ron Bentsur,... the call. Keryx will announce its financial resu...d prior to the call. ,, In order to participate...
(Date:11/6/2009)...irstCall/ -- Caraco Pharmaceutical Laboratories, L...ethamine ophthalmic solution, 0.5% following a fin...on (FDA) for Sun Pharma,s Abbreviated New Drug App... solution on the first day following patent expira...y equivalent to Acular® Ophthalmic Solution, ...
(Date:11/5/2009)...5 Transcept Pharmaceutic...ical company focused on the development and commer...mportant therapeutic needs in the field of neurosc...teleconference with management to discuss third qu... 12, 2009, at 5:00 p.m. Eastern Standard Time. Fi...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2The Vision Revolution 3A Eyes are the source of human superpowers 8866 1The Vision Revolution 3A Eyes are the source of human superpowers 8866 2GlaxoSmithKline 13th Annual IMPACT Awards Seek Nonprofits Providing Access to Healthcare 49110 1GlaxoSmithKline 13th Annual IMPACT Awards Seek Nonprofits Providing Access to Healthcare 49110 2Doctor Diabetic Supply Inc Acquires Diabetes Source Rx 49107 1Doctor Diabetic Supply Inc Acquires Diabetes Source Rx 49107 2
...Aug. 26 Omeros Corporation today announced the,pu...ial investigating,OMS103HP in arthroscopic anterio...OMS103HP is an investigational drug product that i... designed to improve postoperative,knee function a...ients an,earlier return to work. The article title...
...alls it a ,miracle, LATHAM, N.Y., Aug. 25 Clinic...am at Community Care Physicians in,Latham have com...,radiotherapy technology from Varian Medical Syste...ighly-precise image-guided,intensity-modulated rad..., RapidArc treatments spare healthy tissue and ot...
Other Medicine Technology:Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3
(Date:11/7/2009)...wswire-USNewswire/ -- The American Medical Associa...of Health at the Family Violence Prevention Fund, ...at its semi-annual policy-making meeting. The Cit...or the AMA House of Delegates bestows on a non-phy...gi-bin/prnh/20081209/AMALOGO ) ,, "Ms. James ...
(Date:11/7/2009)...wswire-USNewswire/ -- Members of the AMA are tryin...esolution rescinding the AMA,s support of HR 3962....e responsible to their PATIENTS, not the leadershi...licy for the Association of American Physicians an... other medical groups. ,, "If the AMA leadersh...
(Date:11/7/2009)...RNewswire-USNewswire/ -- The U.S. bishops November...o vote for the Stupak-Ellsworth Amendment to the h...ts-Kaptur-Dahlkemper-Lipinski-Smith Amendment will...ding and conscience protections in the Affordable ...d. ,, The letter was signed by Cardinal Justin ...
(Date:11/7/2009)...ic Relations Society of America (PRSA) will bestow...ofgren, senior vice president of Brand Strategy, C...t at a ceremony at PRSA,s 2009 International Confe...PRSA College of Fellows is one of the profession,s...APR, SAGE, Fellow PRSA, and 2009 chair of the Coll...
(Date:11/7/2009)...tober 23-25th marked the 12th annual tournament br...he battle against pediatric cancer. Stephen Updeg...forts for many years. , S...e weekend of October 23-25 marked the 12th annual...ies fighting the battle against pediatric cancer&n...
Breaking Medicine News(10 mins):Health News:AMA Honors Family Violence Prevention Expert 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3
...dice and hope they come up seven: on Saturday thou...rt city to gamble that the lucky number holds the...tal of the world, couples are lining up to get mar...weddings for decades and at large glitzy resorts w...
...lantable cardioverter defibrillators in Canada is ...hat in the United States. Dr. David Birnie and col...ute report that, between 1995 and 2003, the use of...rom 9.7% to 42.0%. Implantable cardioverter ...
... huggers but now by Madonna, Sting and other stars... adopted as a celebrity campaign issue in Saturda...istory, climate change has faced indifference or i...eenmongering scare. Thirty years ago, only...
...search teams at Glasgow University and Baylor Coll...regulators of SCC development, providing insights...isease. Squamous cell carcinoma (SCC) is a fo... in the p53 tumor suppressor gene have been implic...
...nal Cricket Council (ICC) and the Pakistan Cricket...doping rules , the World-Anti Doping Agency (WADA)...verely hampered if this is not take care of. ...ensure that their anti-doping rules are able to av...
...announced that with the initiation of a new study ...geles, it will accelerate the recruitment of pati...dy of EPC2407, a novel small molecule vascular dis...ve been completed according to schedule at Scottsd...
Other Medicine News:Health News:Will Seven Be the Lucky Number for Las Vegas Newlyweds? 2Health News:Live Earth: How Global Warming Became Cool 2Health News:Live Earth: How Global Warming Became Cool 3Health News:Skin Cancer can Be Triggered by P53 Mutation 2Health News:Anti-doping Rules Must Avoid Unsatisfactory Decisions: WADA 2Health News:EpiCept Accelerates Development of Phase I Clinical Study for Cancer 2
MSV-10 Adjustable Velcro
Wide Belt Wrap Around
Wide Belt
Vari-Stim® Hand-Held Nerve Locator/Stimulator
Medicine Products: